LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

<
<<
Previous
Page 1 of 520
Next
>>
>
1 to 25 of 12982 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Seliciclib	3.33	uM	LJP5	3	J02	72	hr	1334	3520	4117	0.8549	0.8161
BT-20	AT-7519	0.12	uM	LJP6	2	K05	72	hr	1334	4021	3899	1.0313	1.0402
BT-20	Seliciclib	0.37	uM	LJP5	1	J04	72	hr	1334	3849	3930	0.9792	0.9732
BT-20	Seliciclib	3.33	uM	LJP5	2	J02	72	hr	1334	3647	4051	0.9003	0.8730
BT-20	AT-7519	0.04	uM	LJP6	1	K06	72	hr	1334	3808	3955	0.9626	0.9520
BT-20	AT-7519	0.12	uM	LJP6	1	K05	72	hr	1334	3836	3955	0.9697	0.9612
BT-20	Seliciclib	0.04	uM	LJP5	3	J06	72	hr	1334	4067	4117	0.9877	0.9848
BT-20	Seliciclib	0.12	uM	LJP5	3	J05	72	hr	1334	3871	4117	0.9401	0.9254
BT-20	Seliciclib	1.11	uM	LJP5	1	J03	72	hr	1334	3702	3930	0.9418	0.9245
BT-20	Seliciclib	3.33	uM	LJP5	1	J02	72	hr	1334	3159	3930	0.8037	0.7383
BT-20	Seliciclib	10	uM	LJP5	2	J01	72	hr	1334	1837	4051	0.4535	0.2207
BT-20	Seliciclib	10	uM	LJP5	3	J01	72	hr	1334	1688	4117	0.4099	0.1555
BT-20	AT-7519	0.04	uM	LJP6	2	K06	72	hr	1334	3887	3899	0.9969	0.9960
BT-20	AT-7519	0.04	uM	LJP6	3	K06	72	hr	1334	3548	3921	0.9048	0.8754
BT-20	Seliciclib	0.04	uM	LJP5	1	J06	72	hr	1334	4134	3930	1.0517	1.0658
BT-20	Seliciclib	0.04	uM	LJP5	2	J06	72	hr	1334	4081	4051	1.0074	1.0092
BT-20	Seliciclib	0.12	uM	LJP5	1	J05	72	hr	1334	3991	3930	1.0153	1.0196
BT-20	Seliciclib	0.12	uM	LJP5	2	J05	72	hr	1334	4160	4051	1.0269	1.0334
BT-20	Seliciclib	0.37	uM	LJP5	2	J04	72	hr	1334	3836	4051	0.9469	0.9330
BT-20	Seliciclib	0.37	uM	LJP5	3	J04	72	hr	1334	3792	4117	0.9209	0.9012
BT-20	Seliciclib	1.11	uM	LJP5	2	J03	72	hr	1334	3942	4051	0.9731	0.9662
BT-20	Seliciclib	1.11	uM	LJP5	3	J03	72	hr	1334	3837	4117	0.9318	0.9150
BT-20	Seliciclib	10	uM	LJP5	1	J01	72	hr	1334	1648	3930	0.4193	0.1449
BT-20	AT-7519	0.37	uM	LJP6	1	K04	72	hr	1334	3006	3955	0.7599	0.6786
BT-20	AT-7519	0.12	uM	LJP6	3	K05	72	hr	1334	3647	3921	0.9300	0.9088

<
<<
Previous
Page 1 of 520
Next
>>
>
1 to 25 of 12982 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)